RxDoctor Payments Data

Joud Dib, MD

Cardiovascular Disease · Waterloo, IANPI 1033273628

Payments from drug & device makers

$837in general payments, 2019–2025

Across 42 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$554
  • Boston Scientific$148
  • Inari Medical, Inc.$48
  • Abbott$42
  • Cardiovascular Systems Inc.$19
  • AstraZeneca$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$82398%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$837 in reported general payments places this provider in the 35th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$531,653
Medicare patients
1,768
Services billed
7,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban757$798,190
EliquisApixaban532$545,868
EntrestoSacubitril/Valsartan52$43,759
BrilintaTicagrelor44$38,143
Repatha SureclickEvolocumab49$33,744
JardianceEmpagliflozin43$29,942
Repatha SyringeEvolocumab32$17,280
ClopidogrelClopidogrel Bisulfate1,275$14,746
Metoprolol Succinate1,042$14,601
Ranolazine ErRanolazine72$10,008
MultaqDronedarone Hcl12$8,634
Amiodarone Hcl509$8,448
Atorvastatin Calcium953$8,403
Flecainide Acetate164$8,277
Isosorbide Mononitrate ErIsosorbide Mononitrate384$7,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$14$38,14344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →